Although the rate of glaucoma progression varies widely between patients, and prognostic factors to identify patients at higher risk for faster progression have been identified, the answer to the question of whether there are certain subgroups of patients who should be treated more aggressively than others is "no."
Descemet's membrane detachment and posterior wound gape, when they occur, develop very early after cataract surgery and decrease thereafter, while the incidence of posterior wound retraction emerges more slowly but is present in most eyes by 3 years postoperatively.
In patients with progressive optic nerve sheath meningiomas, fractionated stereotactic radiotherapy is the standard of care and prevents further vision loss.
The answer to the question of whether it is necessary to diagnose and treat pre-perimetric glaucoma is not a simple "yes" or "no."
The addition of intraoperative aberrometry to proper preoperative measurements and available clinical history improves refractive and functional outcomes after cataract surgery with accomudating IOL implantation in postLASIK patients.
The use of anti-vascular endothelial growth factor agents in patients with neovascular age-related macular degeneration has revolutionized the treatment of this disease, but concerns about the increased risk for elevated IOP with these agents continue to trouble ophthalmologists.
Accuracy of IOL power prediction using ray tracing is improving and approaching the performance of traditional regression formulae
Careful use of anti-vascular endothelial growth factor agents for the treatment of age-related macular degeneration is acceptable, but physicians should be alert for exceptions to the expected outcome.
Some practical advice and common-sense tips can help clinicians stay abreast of developments and possible malpractice cases.
Most eye-care practitioners are unlikely to read any journal cover to cover, and perhaps they may consider meibomian gland dysfunction underwhelming as a topic at a time when there are a number of exciting developments in vision research.
Results from a phase III study investigating intravitreal ranibizumab for the treatment of DME show that the anti-vascular endothelial growth factor agent was well-tolerated and met its primary efficacy endpoint.
The recently published report from the International Workshop on Meibomian Gland Dysfunction provides an evidence-based review of current knowledge about meibomian gland structure and function in health and disease, offers an idea bank for researchers with an interest in the field, and provides practical guidance to clinicians on the evaluation and management of a very common disorder.
After enduring several disappointing drug trials of treatments that once held promise for dry eye and cystic fibrosis, Inspire Pharmaceuticals will become part of Merck & Co. Inc. in a $430 million acquisition.
If you feel that you have flow issues in your office, stop being the technician's safety valve for poor behavior.
A new quinazolinone compound represents a novel approach to management of choroidal neovascularization.
Periocular injections of steroids improve active inflammation and macular edema in most patients with uveitis.
Sustained release fluocinolone acetonide has the potential to become an effective long-term treatment for DME.
Measure your inventory turns monthly.
The author discusses how MGD is a major source of morbidity and decreased quality of life for patients.
The pivotal study of a sustained-release dexamethasone intravitreal implant showed that it was a safe, effective option for the treatment of noninfectious intermediate and posterior uveitis.
In patients who have not undergone previous treatment, bevacizumab appears to be a safe and effective treatment for exudative age-related macular degeneration.
The key success factor for turning ideas into reality is planning.
Most aspects of ocular trauma are unique when practicing in a combat environment.
A single intravitreal injection of ocriplasmin is safe, effective, well-tolerated, and is the first pharmacologic treatment for symptomatic vitreomacular adhesion.
On March 16, LENSAR Inc. received 510 (k) clearance from the FDA to market its femtosecond laser system for lens fragmentation in addition to anterior capsulotomy during cataract surgery.
